canrenone has been researched along with Endomyocardial Fibrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagrov, AY; Cooper, CJ; El-Okdi, N; Elkareh, J; Fedorova, OV; Gohara, S; Gupta, S; Haller, S; Malhotra, D; Periyasamy, SM; Shapiro, JI; Shidyak, A; Taleb, M; Tian, J; Xie, Z | 1 |
| Sanderson, JE | 1 |
| Casaburi, C; Cittadini, A; Di Gianni, A; Monti, MG; Saccà, L; Saldamarco, L; Scherillo, G; Serpico, R; Vanasia, M | 1 |
3 other study(ies) available for canrenone and Endomyocardial Fibrosis
| Article | Year |
|---|---|
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Topics: Animals; Bufanolides; Canrenone; Cardiomyopathies; Cardiotonic Agents; Cells, Cultured; Disease Models, Animal; Drug Interactions; Endomyocardial Fibrosis; Fibroblasts; Mineralocorticoid Receptor Antagonists; Myocardium; Nephrectomy; Ouabain; Procollagen; Proline; Rats; Renal Insufficiency; Spironolactone; Tritium; Uremia | 2009 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; Endomyocardial Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Spironolactone | 2002 |
Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure.
Topics: Administration, Oral; Aldosterone; Animals; Canrenone; Collagen; Cyclodextrins; Disease Models, Animal; Dose-Response Relationship, Drug; Endomyocardial Fibrosis; gamma-Cyclodextrins; Heart Failure; Hemodynamics; Hydroxyproline; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Ventricular Function, Left | 2002 |